15 May 2024 by admin in UncategorizedComments Sail Biomedicines Appoints Clinical and Scientific Leader Dr. Wendy Chung to Its Board
15 May 2024 by admin in UncategorizedComments Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
07 May 2024 by admin in UncategorizedComments Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
06 May 2024 by admin in UncategorizedComments Adcentrx Therapeutics Announces China NMPA Grants IND Clearance for ADRX-0706, a Novel Nectin-4 ADC for the Treatment of Advanced Solid Tumors
30 Apr 2024 by admin in UncategorizedComments Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for EB-105 – A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) – and Upcoming Scientific Presentations
08 Apr 2024 by admin in UncategorizedComments Adcentrx Therapeutics Appoints Meng Jiang as Chief Financial Officer
29 Mar 2024 by admin in UncategorizedComments Alebund’s Innovative Investigational Drug AP303 Receives FDA Orphan Drug Designation (ODD) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
26 Mar 2024 by admin in UncategorizedComments Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline
06 Mar 2024 by admin in UncategorizedComments Zenas BioPharma Appoints Patricia Allen to its Board of Directors
07 Feb 2024 by admin in UncategorizedComments Sail Biomedicines Appoints Kerry Benenato, Ph.D., as Chief Platform Officer
29 Jan 2024 by admin in UncategorizedComments Oricell Announces FDA Clearance of IND Application for OriCAR- 017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company’s Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma
25 Jan 2024 by admin in UncategorizedComments Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
18 Jan 2024 by admin in UncategorizedComments NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
15 Jan 2024 by admin in UncategorizedComments Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines
04 Jan 2024 by admin in UncategorizedComments Sail Biomedicines Appoints Tech and Pharma Industry Veteran Frank D’Amelio to Its Board
03 Jan 2024 by admin in UncategorizedComments Sail Biomedicines Receives Grants to Fight Malaria by Developing a New Class of RNA Medicines
19 Dec 2023 by admin in UncategorizedComments Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
13 Dec 2023 by admin in UncategorizedComments Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan- inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis
06 Dec 2023 by admin in UncategorizedComments Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
06 Dec 2023 by admin in UncategorizedComments Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC
05 Dec 2023 by admin in UncategorizedComments Adcentrx Announces Extension of Series A+ Financing to $51 Million
05 Dec 2023 by admin in UncategorizedComments Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer
04 Dec 2023 by admin in UncategorizedComments Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer
15 Nov 2023 by admin in UncategorizedComments ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
19 Oct 2023 by admin in UncategorizedComments Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to form Sail
02 Oct 2023 by admin in UncategorizedComments Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company
19 Sep 2023 by admin in UncategorizedComments Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
12 Sep 2023 by admin in UncategorizedComments Kira Pharmaceuticals Presents Complete Data from Phase 1 SYNERGY-1 Trial of KP104 and Preclinical Studies in Autoimmune Skin Disease Models from Collaboration with University of Lübeck at the 29th International Complement Workshop (ICW 2023)
07 Sep 2023 by admin in UncategorizedComments NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen
05 Sep 2023 by admin in UncategorizedComments Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb
04 Sep 2023 by admin in UncategorizedComments Crescendo Biologics Wins Significant European Patent Office Ruling Related to the Engineering of Immunoglobulin Therapeutics
18 Aug 2023 by admin in UncategorizedComments Eluminex Biosciences Completes Series B+ Financing, Raising More Than $50 M in 2023
14 Aug 2023 by admin in UncategorizedComments Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
10 Aug 2023 by admin in UncategorizedComments Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact
24 Jul 2023 by admin in UncategorizedComments Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours
17 Jul 2023 by admin in UncategorizedComments Alebund Achieved First Patient Enrolment for AP301 Pivotal Phase 3 Clinical Trial and Successfully Held Investigator Meeting in Beijing
11 Jul 2023 by admin in UncategorizedComments Adicet Announces Appointment of Katie Peng to the Board of Directors
